ArticleFrontiers in oncology2025
Lymph node metastasis in patients with hepatocellular carcinoma using machine learning: a population-based study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aims to develo\p a population-adapted machine learning-based prediction model for hepatocellular carcinoma (HCC) lymph node metastasis (LNM) to identify high-risk patients requiring intensive surveillance. Methods: Data from 23511 HCC patients in the SEER database and 57 patients from our hospital were analyzed. Seven LNM risk indicators were selected. Four machine learning algorithms-decision tree (DT), logistic Regression (LR), multilayer perceptron (MLP), and extreme gradient boosting (XGBoost)-were employed to construct prediction models. Model performance was evaluated using area under the curve, accuracy, sensitivity, and specificity. Results: Among 23511 SEER patients, 1679 (7.14%) exhibited LNM. Race, Sequence number, Tumor size, T stage and AFP were identified as independent predictors of LNM. The LR model achieved optimal performance (area under the curve: 0.751; accuracy: 0.707; sensitivity: 0.711; specificity: 0.661). External validation with 57 patients from our hospital confirmed robust generalizability (area under the curve: 0.73; accuracy: 0.737; sensitivity: 0.829; specificity: 0.5), outperforming other models. Conclusions: The LR-based model demonstrates superior predictive capability for LNM in HCC, offering clinicians a valuable tool to guide personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.